Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

The Vitamins in Psychosis Study: A Randomized, Double-Blind, Placebo-Controlled Trial of the Effects of Vitamins B12, B6, and Folic Acid on Symptoms and Neurocognition in First-Episode Psychosis.

Allott K, McGorry PD, Yuen HP, Firth J, Proffitt TM, Berger G, Maruff P, O'Regan MK, Papas A, Stephens TCB, O'Donnell CP.

Biol Psychiatry. 2019 Jul 1;86(1):35-44. doi: 10.1016/j.biopsych.2018.12.018. Epub 2019 Jan 9.

PMID:
30771856
2.

Iterative Assembly of Macrocyclic Lactones using Successive Ring Expansion Reactions.

Stephens TC, Lawer A, French T, Unsworth WP.

Chemistry. 2018 Sep 18;24(52):13947-13953. doi: 10.1002/chem.201803064. Epub 2018 Aug 19.

3.

A Coupling Approach for the Generation of α,α-Bis(enolate) Equivalents: Regioselective Synthesis of gem-Difunctionalized Ketones.

Iacono CE, Stephens TC, Rajan TS, Pattison G.

J Am Chem Soc. 2018 Feb 14;140(6):2036-2040. doi: 10.1021/jacs.7b12941. Epub 2018 Feb 5.

PMID:
29381360
4.

Synthesis of Cyclic Peptide Mimetics by the Successive Ring Expansion of Lactams.

Stephens TC, Lodi M, Steer AM, Lin Y, Gill MT, Unsworth WP.

Chemistry. 2017 Sep 27;23(54):13314-13318. doi: 10.1002/chem.201703316. Epub 2017 Aug 9.

5.

Transition-Metal-Free Homologative Cross-Coupling of Aldehydes and Ketones with Geminal Bis(boron) Compounds.

Stephens TC, Pattison G.

Org Lett. 2017 Jul 7;19(13):3498-3501. doi: 10.1021/acs.orglett.7b01474. Epub 2017 Jun 13.

PMID:
28605914
6.

Ring-Expansion Approach to Medium-Sized Lactams and Analysis of Their Medicinal Lead-Like Properties.

Baud LG, Manning MA, Arkless HL, Stephens TC, Unsworth WP.

Chemistry. 2017 Feb 10;23(9):2225-2230. doi: 10.1002/chem.201605615. Epub 2017 Jan 18.

PMID:
27935197
7.

Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.

Appels NM, Bolijn MJ, van Eijndhoven MA, Stephens TC, Beijnen JH, Schellens JH.

Cancer Chemother Pharmacol. 2011 Jan;67(1):137-45. doi: 10.1007/s00280-010-1300-6. Epub 2010 Mar 13.

PMID:
20229082
8.

Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.

Appels NM, Bolijn MJ, Chan K, Stephens TC, Hoctin-Boes G, Middleton M, Beijnen JH, de Bono JS, Harris AL, Schellens JH.

Br J Cancer. 2008 Jun 17;98(12):1951-8. doi: 10.1038/sj.bjc.6604402. Epub 2008 May 27.

9.

Regulation of tumor signaling pathways by AZD3409 in vitro.

Streeper R, Campos D, Carrizales G, Stephens TC, Izbicka E.

Anticancer Res. 2006 Nov-Dec;26(6B):4185-9.

10.

Radiosensitizing effects of the prenyltransferase inhibitor AZD3409 against RAS mutated cell lines.

Cengel KA, Deutsch E, Stephens TC, Voong KR, Kao GD, Bernhard EJ.

Cancer Biol Ther. 2006 Sep;5(9):1206-10. Epub 2006 Sep 11.

PMID:
16969121
12.

Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry.

Appels NM, Rosing H, Stephens TC, Hughes A, Schellens JH, Beijnen JH.

Anal Biochem. 2006 May 1;352(1):33-40. Epub 2006 Mar 20.

PMID:
16564488
13.

Tumor penetration of gefitinib (Iressa), an epidermal growth factor receptor tyrosine kinase inhibitor.

McKillop D, Partridge EA, Kemp JV, Spence MP, Kendrew J, Barnett S, Wood PG, Giles PB, Patterson AB, Bichat F, Guilbaud N, Stephens TC.

Mol Cancer Ther. 2005 Apr;4(4):641-9.

14.
15.

Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase.

Jackman AL, Kimbell R, Aherne GW, Brunton L, Jansen G, Stephens TC, Smith MN, Wardleworth JM, Boyle FT.

Clin Cancer Res. 1997 Jun;3(6):911-21.

16.

Preclinical pharmacology of CB30900, a novel dipeptide inhibitor of thymidylate synthase, in mice.

Walton MI, Gibson W, Aherne GW, Lawrence N, Stephens TC, Smith MN, Jackman AL.

J Pharmacol Exp Ther. 1996 May;277(2):909-16.

PMID:
8627573
17.

ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer.

Jackman AL, Farrugia DC, Gibson W, Kimbell R, Harrap KR, Stephens TC, Azab M, Boyle FT.

Eur J Cancer. 1995 Jul-Aug;31A(7-8):1277-82. Review.

PMID:
7577036
18.

Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.

Stephens TC, Smith MN, Waterman SE, McCloskey ML, Jackman AL, Boyle FT.

Adv Exp Med Biol. 1993;338:589-92. No abstract available.

PMID:
8304186
19.

Substituted-2-desamino-2-methyl-quinazolinones. A series of novel antitumour agents.

Boyle FT, Matusiak ZS, Hughes LR, Slater AM, Stephens TC, Smith MN, Brown M, Kimbell R, Jackman AL.

Adv Exp Med Biol. 1993;338:585-8. No abstract available.

PMID:
8304185
20.

Gamma-linked dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8- dideazafolate as antitumour agents.

Jackman AL, Bisset GM, Jodrell DI, Gibson W, Kimbell R, Bavetsias V, Calvert AH, Harrap KR, Stephens TC, Smith MN, et al.

Adv Exp Med Biol. 1993;338:579-84.

PMID:
8304184
21.

ICI D1694, an inhibitor of thymidylate synthase for clinical study.

Jackman AL, Jodrell DI, Gibson W, Stephens TC.

Adv Exp Med Biol. 1991;309A:19-23.

PMID:
1789205
22.

UKCCCR guidelines for the welfare of animals in experimental neoplasia.

Workman P, Balmain A, Hickman JA, McNally NJ, Rohas AM, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC, et al.

Lab Anim. 1988 Jul;22(3):195-201. No abstract available.

PMID:
3172698
23.

Split-dose and low dose-rate recovery in four experimental tumour systems.

Stephens TC, Eady JJ, Peacock JH, Steel GG.

Int J Radiat Biol Relat Stud Phys Chem Med. 1987 Jul;52(1):157-70.

PMID:
3496307
24.

Development of MeCCNU-resistance in clonally derived lines of Lewis lung carcinoma.

McMillan TJ, Stephens TC, Peacock JH, Steel GG.

Eur J Cancer Clin Oncol. 1987 Jun;23(6):801-5.

PMID:
3653197
25.

Clonal variation in the sensitivity of a murine mammary carcinoma to melphalan.

McMillan TJ, Stephens TC, Steel GG.

Br J Cancer. 1986 Jun;53(6):753-9.

26.

Dose-rate effects and the repair of radiation damage.

Steel GG, Down JD, Peacock JH, Stephens TC.

Radiother Oncol. 1986 Apr;5(4):321-31.

PMID:
3726169
27.
28.

Temporal interactions in the Lewis lung tumour between cytotoxic drugs and acute or fractionated radiotherapy.

Stephens TC, Adams K, Peacock JH, Steel GG.

Radiother Oncol. 1986 Feb;5(2):137-46.

PMID:
3704188
29.

Radiosensitivity of the B16 melanoma is not significantly influenced by melanin content.

Stephens TC, Adams K, Peacock JH.

Int J Radiat Biol Relat Stud Phys Chem Med. 1986 Jan;49(1):169-75. No abstract available.

PMID:
3484468
30.

Development of drug resistance in a murine mammary tumour.

McMillan TJ, Stephens TC, Steel GG.

Br J Cancer. 1985 Dec;52(6):823-32.

31.

Adriamycin sensitivity following "ultra" low dose rate irradiation of Lewis lung carcinoma in vivo.

Peacock JH, Shipley WU, Steel GG, Stephens TC.

Int J Radiat Oncol Biol Phys. 1985 Dec;11(12):2099-104.

PMID:
4066442
32.

Kinetics of cellular inactivation by fractionated and hyperfractionated irradiation in Lewis lung carcinoma.

Beck-Bornholdt HP, Peacock JH, Stephens TC.

Int J Radiat Oncol Biol Phys. 1985 Jun;11(6):1171-7.

PMID:
3997599
33.
34.
35.

Continuous irradiation of the Lewis lung carcinoma in vivo at clinically-used "ultra" low-dose-rates.

Shipley WU, Peacock JH, Steel GG, Stephens TC.

Int J Radiat Oncol Biol Phys. 1983 Nov;9(11):1647-53.

PMID:
6643160
36.

Clonal variation in the sensitivity of B16 melanoma to m-AMSA.

Stephens TC, Peacock JH.

Br J Cancer. 1982 Jun;45(6):821-9.

37.

The effect of cytotoxic drugs with or without misonidazole on leucopenia in three strains of mice.

McNally NJ, Stephens TC, Twentyman PR, Hinchliffe M, Peacock JH, Spooner D.

Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):659-62.

PMID:
7107394
38.

Enhancement of cytotoxic drugs by misonidazole (MISO) in Lewis lung tumors of different sizes, and mouse bone marrow.

Spooner D, Peacock JH, Stephens TC.

Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):643-6.

PMID:
7107390
39.

An explanation for the ability of cytotoxic drug pretreatment to reduce bone marrow related lethality of total body irradiation (TBI).

Millar JL, Stephens TC, Wist EA.

Int J Radiat Oncol Biol Phys. 1982 Mar-Apr;8(3-4):581-3. No abstract available.

PMID:
7050041
40.

Response of two mouse tumours to hyperthermia with CCNU or melphalan.

Joiner MC, Steel GG, Stephens TC.

Br J Cancer. 1982 Jan;45(1):17-26.

41.
42.

Influence of in vitro assay conditions on the assessment of radiobiological parameters of the MT tumour.

Stephens TC, Peacock JH, Sheldon PW.

Br J Radiol. 1980 Dec;53(636):1182-7.

PMID:
7437731
44.
45.

Cell yield and cell survival following chemotherapy of the B16 melanoma.

Stephens TC, Peacock JH.

Br J Cancer. 1978 Nov;38(5):591-8.

46.
47.

Clonogenic assays in the B16 melanoma: response to cyclophosphamide.

Steel GG, Adams K, Stephens TC.

Br J Cancer. 1977 Nov;36(5):618-24.

49.
50.

Proceedings: Mechanism of action studies with IRCF 159: effects on the growth and morphology of BHK-21S cells.

Stephens TC, Creighton AM.

Br J Cancer. 1974 Jan;29(1):99-100. No abstract available.

Supplemental Content

Loading ...
Support Center